Jonathan Alicea

Animal models suggest the investigative treatment is safe and tolerable in treating retinal vascular diseases.

There were no significant differences between dexamethasone and fluocinolone acetonide intravitreal implants in controlling inflammation; however, the latter is considered more difficult to use.

Up to 77% of patients maintained or improved best-corrected visual acuity at 12 month post-injection.

Hispanic and Black patients with chronic eye diseases had higher odds of missing out on appointments.

Investigators report a low incidence rate of unscheduled or urgent visits within 7 days of injection.

Patients with nAMD, DME, and RVO received fewer intravitreal injections between pre- and post-lockdown periods.

These findings corroborate similar conclusions presented last year at ARVO.

Age-adjusted glaucoma blindness has nonetheless seen a downward trend between 2000 and 2020.

The single-injection investigative gene therapy may help with providing continuous expression of aflibercept.

The AAV8 vector–based gene therapy was associated with improvements in 2 measures of visual function.

The majority of patients with a treatment gap longer than 12 weeks had worsening visual acuity, notes a new ARVO study.

The twice-daily oral agent is indicated for patients ≥3 years of age

More research is needed to fully understand the associations with different types of strabismus

Patients with diabetes mellitus have the highest odds of being diagnosed with an undetected eye disease.

The PACIFIC study is currently evaluating health care management practice with intravitreal ranibizumab 0.5 mg for various ophthalmologic diseases.

An ARVO 2021 study characterizes patients with diabetic retinopathy who have also developed diabetic macular edema.

A cohort analysis of African American patients finds an association between 1-year ozone concentrations and diagnosed incident diabetes at clinical visit.

The nasal spray can be administered by anyone regardless of medical training.

Marla Dubinsky, MD, discusses what needs to be done to improve care for children with ulcerative colitis.

Not all individuals with sarcoidosis need to be treated.

Patients with multiple hospital visits were more likely to utilize more than one (conventional and/or alternative) pain relief technique.

Marla Dubinsky, MD, discusses what adding adalimumab to the pediatric ulcerative colitis toolbox means for treatment strategies.

While Janus Kinase inhibitors are a fraction of what’s to come in dermatology, research from AAD VMX 2021 shows they represent the potential of unlocking new capabilities across the field.

Jeffrey Stark, MD, of UCB discusses the promising data being generated by the robust trial program for plaque psoriasis.

Esther Freeman, MD, PhD, discusses the most frequent cutaneous presentations associated with vaccination.

The Head of Immunology Medical Affairs at UCB discusses what bimekizumab is and how it works.

The Phase 2b study shows a higher proportion of ligelizumab-treated patients achieved complete response or lower severity score compared with omalizumab.

All patients treated with 2.5 benzoyl peroxide and a stabilized cosmetic retinol saw significant improvement in lesion count reduction after 12 weeks.

Implementing alternative therapies does not mean abandoning conventional medications, stresses Peter Lio, MD. There must be a balance that works for the patient's situation.

Seemal Desai, MD, gives an overview of the most promising research and therapies for patient of color populations.